滚动资讯
FierceBiotechKBP hopes to revive troubled heart drug at center of deal fraud dispute with Novo NordiskFierceBiotechIterum initiates wind-down after failure to offload antibiotic with sluggish salesEndpoints NewsPharma goes on $25.5B, eight-day acquisition spreeEndpoints NewsAstraZeneca's next-gen hopeful for a rare bone condition fails pivotal trial10x Genomics BlogBioptimus launches massive patient data atlas to train its biology AI - R&D WorldIlluminaIllumina (ILMN) Valuation Check As Labcorp Partnership Expands In Precision Oncology - simplywall.stEndpoints NewsFDA identifies eight deaths tied to Amgen's TavneosWatersWaters Corporation Stock: Analytical Instruments Leader Positions for Growth Amid Strategic Acquisit - AD HOC NEWSAgilentComparison Of Different Methods To Isolate HMW DNA From Bacteria For Nanopore Sequencing - Bioprocess OnlineThermo FisherThermo Fisher's Glacios 3 Cryo-TEM targets the renovation barrier that has kept cryo-EM out of reach - R&D WorldLonza NewsLonza Strengthens Board With Nomination of Former Eli Lilly Executive Stephen Fry - TipRanks10x Genomics Blog10x Genomics Seen As Key Player In AI-Driven Biological Data Buildout - 10x Genomics (NASDAQ:TXG) - Benzinga
FierceBiotech 2026年4月1日

KBP hopes to revive troubled heart drug at center of deal fraud dispute with Novo Nordisk

KBP hopes to revive troubled heart drug at center of deal fraud dispute with Novo Nordisk

原文
暂时没有全文，请查看原始来源。

目录

59 全部